M.E. Jones
MRL Pharmaceutical Services
Utrecht
Netherlands
Name/email consistency: high
- Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 1997-1998 respiratory season. Jones, M.E., Sahm, D.F., Martin, N., Scheuring, S., Heisig, P., Thornsberry, C., Köhrer, K., Schmitz, F.J. Antimicrob. Agents Chemother. (2000)
- Multiple mutations conferring ciprofloxacin resistance in Staphylococcus aureus demonstrate long-term stability in an antibiotic-free environment. Jones, M.E., Boenink, N.M., Verhoef, J., Köhrer, K., Schmitz, F.J. J. Antimicrob. Chemother. (2000)
- Benchmarking the in vitro activity of moxifloxacin against recent isolates of Streptococcus pneumoniae, Moraxella catarrhalis, and Haemophilus influenzae. A European multi-centre study. Jones, M.E., Staples, A.M., Critchley, I., Thornsberry, C., Heinze, P., Engler, H.D., Sahm, D.F. Diagn. Microbiol. Infect. Dis. (2000)
- Benchmarking the in vitro activities of moxifloxacin and comparator agents against recent respiratory isolates from 377 medical centers throughout the United States. Jones, M.E., Staples, A.M., Critchley, I., Thornsberry, C., Heinze, P., Engler, H.D., Sahm, D.F. Antimicrob. Agents Chemother. (2000)
